PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35397768-4	2022	To develop a population pharmacokinetic model for midazolam in adult intensive care unit patients infected with COVID-19 and to assess the effect of inflammation, reflected by IL-6, on the pharmacokinetics of midazolam.	Midazolam	209-218	interleukin 6	Homo sapiens	176-180	
35397768-12	2022	Midazolam clearance was reduced by increased IL-6 and IL-6 explained more of the variability within our patients than CRP.	Midazolam	0-9	interleukin 6	Homo sapiens	45-49	
35397768-12	2022	Midazolam clearance was reduced by increased IL-6 and IL-6 explained more of the variability within our patients than CRP.	Midazolam	0-9	interleukin 6	Homo sapiens	54-58	
35397768-13	2022	The midazolam clearance was reduced by 24% (6.7-5.1 L/h) when IL-6 increases from population median 116 to 300 pg/mL.	Midazolam	4-13	interleukin 6	Homo sapiens	62-66	
35397768-14	2022	CONCLUSIONS: Inflammation, reflected by high IL-6, reduces midazolam clearance in critically ill patients with COVID-19.	Midazolam	59-68	interleukin 6	Homo sapiens	45-49